I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and now Xconomy.
One year ago, in a paper in the journal Oncoimmunology, three cancer researchers wrote this: “After many years of best efforts and countless dollars, but unmet expectations, cancer vaccines have... Read more »
Nina Kjellson has been a biotech investor for 15 years, having spent the last 13 at InterWest Partners in Menlo Park, CA. Now she’s moving across the street to Canaan Partners.... Read more »
The popular gene-editing system known as CRISPR/Cas9 has become an indispensable biological research tool, and it also holds profound therapeutic, environmental, ethical, and business implications. Now it has a cousin.
Researchers... Read more »
San Francisco Bay Area biotech firm Exelixis (NASDAQ: EXEL) is bringing on board three new executives in anticipation of two drugs gaining FDA approval. The company, trying to turn around... Read more »
It was already a good political time for Hillary Clinton to unveil her plan to control the cost of prescription drugs. Martin Shkreli made it perfect.
As you’ve probably heard by... Read more »
[Corrected 9/22/15, 10:15am. See below.] Call it the Termeer trickle-down effect. Former Genzyme CEO Henri Termeer has been funding and advising Boston-area startups ever since his company was snapped... Read more »
It’s not specific to the West Coast, but anyone who needs to catch up on the week’s events should read the British Medical Journal’s re-analysis of a long-criticized study, dubbed... Read more »
Researchers around the world have explored the ties between the immune system and devastating neurodegenerative diseases such as Alzheimer’s. San Francisco biotech Alector wants to exploit those ties to make drugs,... Read more »
President Obama has nominated cardiologist Rob Califf to be the next head of the Food and Drug Administration, replacing the outgoing Margaret “Peggy” Hamburg.
The nomination is no surprise. Speculation... Read more »
Americans need to spend less on healthcare. Anyone disagree? No country spends like we do: 17 percent of our gross domestic product the past four years, in fact, according to the... Read more »
San Diego-based AnaptysBio, a developer of antibody-based drugs, has placed a stake in the ground to go public, filing IPO paperwork Wednesday.
The 10-year-old firm recently raised a $40 million Series... Read more »
As biotech ended its worst market month since the recession, it was fitting that one of the week’s best stories was about bears. Grizzlies, to be precise. Grizzlies are oh-so-Western, so... Read more »
[Updated 9/3/15, 11:30 am. See below.] Tiny Faraday Pharmaceuticals of Seattle launched last year to try what its predecessor Ikaria couldn’t do: Turn the cutting-edge research of founder Mark... Read more »
For certain parts of the population, “summer” is a verb, and in the U.S., one does it until Labor Day. One more week, then, before sunburned financial types return to their... Read more »
As top scientists head toward a summit later this year to hammer out rules governing the use of gene editing, companies developing one form of the technology, known as CRISPR-Cas9, for... Read more »
[Updated and corrected 8/27/15, 7:28pm, see below.] The new race to fight cholesterol is on. For the second time in a month, the U.S. Food and Drug Administration has... Read more »
The West Coast, according to the self-aggrandizing myth, is a place of re-invention, non-conformism, un-convention. You see this box, man? Our brains are over here, thinking outside of it. It’s all... Read more »
Like countless biotech companies with platform technologies that have preceded it, Seattle’s Adaptive Biotechnologies aims to be a drug company.
Adaptive has made a name for itself by sequencing the cells... Read more »
President and CEO, Biocom
November 17, 2015
© 2007-2015, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.